FIELD: medicine.
SUBSTANCE: invention relates to a method for obtaining antibody-drug conjugates and to antibody-drug conjugates, where an antibody contains a constructed cysteine residue in a position 41 of a heavy chain in accordance with Kabat system, where therapeutic groups are conjugated with one or more constructed cysteine residues, as well as with one or more restored cysteine residues from an interchain connection, by means of a cleavable or non-cleavable linker.
EFFECT: method allows for regulation of DAR of obtained antibody-drug conjugates, obtaining product with insignificant amount of the unreacted antibody; the antibody-drug conjugate has reduced hydrophobicity favorably affecting pharmacokinetic properties of the conjugate.
11 cl, 5 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS WITH ANTIBODIES AND RESULTING ADC | 2015 |
|
RU2773536C2 |
| ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2736720C2 |
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS | 2015 |
|
RU2670157C2 |
| COMPOSITIONS CONTAINING ANTIBODY-DRUG CONJUGATES DUOCARMICIN | 2016 |
|
RU2687237C1 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2806049C2 |
| ANTI-CD71 CONJUGATES ACTIVATED ANTIBODY-DRUG AND THEIR APPLICATION METHODS | 2018 |
|
RU2771292C2 |
| “CYSTEINE-MODIFIED ANTIBODY-DRUG” CONJUGATE AND ITS PRODUCTION METHOD | 2017 |
|
RU2762594C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
